Acquisition - February 18, 2021
Cellink acquires Ginolis
Cellink has entered into an agreement with the shareholders of Ginolis to acquire all shares for a purchase price on cash- and debt-free basis of EUR 70 million. Ginolis is a Finnish company focusing on diagnostics automation and advanced robotics solutions for medical and diagnostic industries, according to Cellink’s press release. “With this strategic acquisition […]
Acquisition - February 18, 2021
Atlas Antibodies acquires HistoCyte Laboratories
Atlas Antibodies has signed an agreement to acquire UK company HistoCyte Laboratories Ltd. HistoCyte Laboratories’ portfolio of cell line materials provides control of immuno-histochemical assays used in the diagnosis of cancers. These materials have tissue-like properties that enhance the quality of tissue-based assays, states Atlas Antibodies in its press-release. “Formed in 2014, HistoCyte Laboratories has […]
Acquisition - February 3, 2021
AstraZeneca to divest Viela shareholding
AstraZeneca has agreed, subject to certain limited exceptions, to divest its 26.7% ownership in Viela Bio, Inc., as part of the proposed acquisition of Viela by Horizon Therapeutics. AstraZeneca is anticipating to receive cash proceeds and profit of c.$760-$780m upon closing for the sale of the holding, which will be recorded in Reported and Core […]
Acquisition - January 18, 2021
OssDsign completes acquisition of bone graft company Sirakoss
OssDsign has completed the acquisition of Sirakoss. The transaction was announced on November 3, 2020. USD 11 million OssDsign has acquired all outstanding Sirakoss shares in an all-cash transaction. The purchase price of USD 11 million, not including agreed milestone and royalty payments, is divided into three cash instalments, of which the first USD 5 […]
Acquisition - January 15, 2021
EQT announces a public offer to the shareholders of Recipharm
In December 2020, EQT IX, through Roar BidCo AB, announced a public offer of SEK 220 in cash per share to the shareholders of Recipharm AB and SEK 1,427,010 in cash per Convertible Bond. The class B shares in Recipharm are listed on Nasdaq Stockholm, Mid Cap. The Convertible Bonds are admitted to trading on […]
Acquisition - January 5, 2021
Nordic Capital and Astorg acquire Cytel
Nordic Capital and Astorg have announced an agreement to jointly acquire Cytel Inc from New Mountain Capital. Cytel is one of the largest providers of statistical software and advanced analytics for clinical trial design and biometrics execution, states the companies. Building on Cytel’s advanced software platform and leading biometrics services offerings, the new owners will […]
